Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia

Hypertension

Volumn 50, Issue 1, 2007, Pages 137-142

  Rana, Sarosh ^a   Karumanchi, S Ananth ^b   Levine, Richard J ^c   Venkatesha, Shivalingappa ^b   Rauh Hain, Jose Alejandro ^d   Tamez, Hector ^d   Thadhani, Ravi ^d  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiangiogenic factors; Predictive test; Preeclampsia; sFlt1; Soluble endoglin

Indexed keywords

ANGIOGENESIS INHIBITOR; CALCIUM; ENDOGLIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; PREECLAMPSIA; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY;

ADULT; ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; CASE-CONTROL STUDIES; FEMALE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; RECEPTORS, CELL SURFACE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34250858133     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.087700     Document Type: Article

References (21)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799.
2. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594.
3. Bdolah Y, Sukhatme VP, Karumanchi SA. Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. Semin Nephrol. 2004;24:548-556.
4. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
5. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
6. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649.
7. Thadhani R, Ecker JL, Kettyle E, Sandler L, Frigoletto FD. Pulse pressure and risk of preeclampsia: A prospective study. Obstet Gynecol. 2001;97:515-520.
8. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: The potential role of inflammation. Obstet Gynecol. 2001;98:757-762.
9. Thadhani R, Stampfer MJ, Hunter DJ, Manson JE, Solomon CG, Curhan GC. High body mass index and hypercholesterolemia: risk of hypertensive disorders of pregnancy. Obstet Gynecol. 1999;94:543-550.
10. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
11. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159-167.
12. Conde-Agudelo A, Villar J, Lindheimer M. World health organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 2004;104:1367-1391.
13. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50:1702-1703.
14. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17:3-18.
15. Stepan H, Unversucht A, Wessel N, Faber R. Predictive Value of Maternal Angiogenic Factors in Second Trimester Pregnancies With Abnormal Uterine Perfusion. Hypertension. 2007;49:818-824.
16. Fisher SJ, Damsky CH Human cytotrophoblast invasion. Semin Cell Biol. 1993;4:183-188.
17. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160:1405-1423.
18. Wathen KA, Tuutti E, Stenman UH, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2006;91:180-184.
19. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol. 2006;291:1085-1093.
20. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. 2002;277:43799-43808.
21. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology. 2004;145:4835-4837.